UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the month of April 2025
Commission
File Number: 001-41115
GENENTA
SCIENCE S.P.A.
(Translation
of Registrant’s Name into English)
Via
Olgettina No. 58
20132
Milan, Italy
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This
report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).
Other
Events
April
2025 Annual Ordinary Shareholders’ Meeting
On
April 29, 2025, Genenta Science S.p.A. (the “Company”) held its Annual Ordinary Shareholders’ Meeting (the “Shareholders’
Meeting”) in virtual meeting format. At the Shareholders’ Meeting, the Company’s shareholders approved the following:
| |
● |
The
statutory financial statements for the year ended December 31, 2024, audited by Revicom. |
| |
|
|
| |
● |
The
appointment of three directors to the Company’s Board of Directors (the “Board”), effective as of April 29, 2025,
of which one individual is a new director. The new member of the Board is Dr. Francesco Galimi. Armon R. Sharei, Ph.D., continued
to serve as a member of the Board. Pierluigi Paracchi, the Company’s Chief Executive Officer, continued to serve on the Board
as Chairman. |
| |
● |
Dr.
Francesco Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private
and public biotech companies as well as large pharma companies. Most recently, he was the Senior Vice President and Chief Medical
Officer of Adicet Bio, Inc. (Nasdaq: ACET), a company focused on allogeneic cell therapy technologies in hemato-oncology and autoimmune
disorders. Previously, he served as the Global Program General Manager at Amgen Inc. (Nasdaq: AMGN), where he led a portfolio of
oncology programs, from pre-IND to late-stage. Prior to Amgen, Dr. Galimi was the Head of Clinical Development at Onyx Pharmaceuticals
Inc. and the Executive Medical Leader at Genomic Institute of the Novartis Research Foundation. Dr. Galimi holds an M.D. from the
University of Torino Medical School with a specialty certification in Medical Oncology and a Ph.D. in Oncology from the University
of Torino Medical School. He conducted his post-doctoral research, with a focus on gene transfer models in hematology, at the Salk
Institute for Biological Studies in La Jolla, California. |
| |
● |
The
term of office of each of the newly appointed directors is one year and the aggregate annual directors’ compensation is €105,000. |
| |
|
|
| |
● |
The
newly appointed directors met the following day (on April 30, 2025) and appointed Mr. Paracchi as Chief Executive Officer of the
Company and allocated €45,000 as annual compensation for Mr. Paracchi and €30,000 as annual compensation for each of Mr.
Galimi and Mr. Sharei. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
GENENTA
SCIENCE S.P.A. |
| |
|
|
| Date:
October 27, 2025 |
By:
|
/s/
Pierluigi Paracchi |
| |
|
Pierluigi
Paracchi, Chief Executive Officer |
